<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1699-714X</journal-id>
<journal-title><![CDATA[Revista de la OFIL ]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. OFIL·ILAPHAR]]></abbrev-journal-title>
<issn>1699-714X</issn>
<publisher>
<publisher-name><![CDATA[Organización de Farmacéuticos Ibero-Latinoamericanos]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1699-714X2022000100018</article-id>
<article-id pub-id-type="doi">10.4321/s1699-714x20220001000018</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Aftas orales refractarias en tratamiento con adalimumab y apremilast en paciente con enfermedad de Behçet. Informe de un caso]]></article-title>
<article-title xml:lang="en"><![CDATA[Refractory oral aftas in treatment with adalimumab and apremilast in patient with Behçet syndrome. A case report]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Proy-Vega]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gómez-Lluch]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alañón-Pardo]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Notario-Dongil]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital General La Mancha-Centro Servicio de Farmacia ]]></institution>
<addr-line><![CDATA[Alcázar de San Juan Ciudad Real]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2022</year>
</pub-date>
<volume>32</volume>
<numero>1</numero>
<fpage>99</fpage>
<lpage>100</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1699-714X2022000100018&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1699-714X2022000100018&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1699-714X2022000100018&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen La enfermedad de Behçet es un trastorno inflamatorio multisistémico que se manifiesta de forma muy variada a nivel cutáneo, especialmente en forma de aftas orales frecuentemente refractarias. Los tratamientos con utilidad en la sintomatología de esta patología, resultan poco específicos y poco efectivos; teniendo que recurrir a veces a tratamientos sistémicos, como los biológicos: entre ellos, los anti-TNF&#945;. Presentamos el caso de una paciente con enfermedad de Behçet, con aftas orales severas, recurrentes y refractarias a múltiples tratamientos. Actualmente, la paciente ha alcanzado la remisión clínica en tratamiento combinado de adalimumab y apremilast.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Summary Behçet's disease is a multisystemic inflammatory disorder that manifests itself in a variety of ways at the cutaneous level, especially in the form of oral thrush, very often very refractory. Treatments that are useful in the symptomatology of this pathology are not very specific and not very effective; sometimes it is necessary to resort to systemic treatments, such as biologi-cal ones: among them, anti-TNF&#945;. We present the case of a patient diagnosed with Behçet's disease, with severe oral aphthae, very recurrent and refractory to multiple treatments. Currently, the patient has reached clinical remission in combined treatment of adalimumab and apremilast.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Apremilast]]></kwd>
<kwd lng="es"><![CDATA[adalimumab]]></kwd>
<kwd lng="es"><![CDATA[Behçet]]></kwd>
<kwd lng="es"><![CDATA[aftas orales]]></kwd>
<kwd lng="es"><![CDATA[refractario]]></kwd>
<kwd lng="en"><![CDATA[Apremilast]]></kwd>
<kwd lng="en"><![CDATA[adalimumab]]></kwd>
<kwd lng="en"><![CDATA[Behçet]]></kwd>
<kwd lng="en"><![CDATA[oral thrush]]></kwd>
<kwd lng="en"><![CDATA[refractary]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martín]]></surname>
<given-names><![CDATA[Jose M]]></given-names>
</name>
<name>
<surname><![CDATA[Mateo]]></surname>
<given-names><![CDATA[Elisabeth]]></given-names>
</name>
<name>
<surname><![CDATA[Monteagudo]]></surname>
<given-names><![CDATA[Carlos]]></given-names>
</name>
<name>
<surname><![CDATA[Jordá]]></surname>
<given-names><![CDATA[Esperanza]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Brote severo de la enfermedad de Behcet con manifestaciones mucocutáneas intensas]]></article-title>
<source><![CDATA[Reumatol Clin]]></source>
<year>2010</year>
<volume>6</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>303-5</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Melikoglu]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Melikoglu]]></surname>
<given-names><![CDATA[M.A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[What affects the quality of life in patients with Behcet's disease?]]></article-title>
<source><![CDATA[Acta Reumatol Port]]></source>
<year>2014</year>
<volume>39</volume>
<numero>2014</numero>
<issue>2014</issue>
<page-range>46-53</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[EPAR Otezla]]></article-title>
<source><![CDATA[EMA]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Taylor]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Glenny]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Walsh]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Interventions for the management of oral ulcers in Behçet's disease]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2014</year>
<numero>9</numero>
<issue>9</issue>
</nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Almoznino]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ben-Chetrit]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Infliximab for the treatment of resistant oral ulcers in Behçet's disease: a case report and review of the literature]]></article-title>
<source><![CDATA[Clin Exp Rheumatol]]></source>
<year>2007</year>
<volume>25</volume>
<numero>4 Suppl 45</numero>
<issue>4 Suppl 45</issue>
<page-range>S99-S102</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sfikakis]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Markomichelakis]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Alpsoy]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Assad-Khalil]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bodaghi]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Gol]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anti-TNF therapy in the man agement of Behçet´s disease: review and bas is recommendations]]></article-title>
<source><![CDATA[Rheumatology]]></source>
<year>2007</year>
<volume>46</volume>
<page-range>736-41</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vallet]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Riviere]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sanna]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients]]></article-title>
<source><![CDATA[J Autoimmun]]></source>
<year>2015</year>
<volume>62</volume>
<page-range>67-74</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="">
<source><![CDATA[ema.europa.eu]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Danesh]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Beroukhim]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Levin]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Koo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Apremilast and adalimumab: a novel combination therapy for recalcitrant psoriasis]]></article-title>
<source><![CDATA[Dermatol Online J]]></source>
<year>2015</year>
<volume>21</volume>
<numero>6</numero>
<issue>6</issue>
</nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="">
<source><![CDATA[Abstract ACR 1725: Combination therapy of apremilast and biologic agent as a safe option of Psoriatic Arthritis and Psoriasis]]></source>
<year></year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
